Background: Endothelial cells (ECs) are responsible for creating a tumor vascular niche as well as producing angiocrine factors. ECs demonstrate functional and phenotypic heterogeneity when located under different microenvironments. Here, we describe a tumor-stimulated mesenchymal phenotype in ECs and investigate its impact on tumor growth, stemness, and invasiveness.
Background
Endothelial cells (ECs) are the building blocks of the vascular system and are characterized as the single-cell layer of epithelium that forms the inner cell lining of blood vessels and lymphatics [1] . Vascular ECs were initially considered passive conduits for delivering oxygen and nutrients to all tissues [2, 3] . The development of appropriate culturing systems for primary human organspecific ECs provided the opportunity to identify EC heterogeneity in different organs as well as their functional properties under normal and pathological conditions [4] [5] [6] . Today, ECs have been implicated in several perfusionindependent processes including tissue regeneration, tumor growth and dormancy through secretion of angiocrine factors [7] [8] [9] [10] [11] [12] [13] [14] . In addition, increasing evidence reveals that endothelial cellular identity is more plastic than previously thought [15] . This plasticity results in phenotypical and functional modifications under different contextual conditions. A characteristic example of such phenotypic modification is endothelial-to-mesenchymal transition (EndMT), during which ECs lose their endothelial phenotype and acquire mesenchymal traits [16] [17] [18] . EndMT is implicated in tumor progression through complex modulation of the tumor and its stroma [17] . It is likely that precise analysis of cellular transformation in tumor microenvironments will reveal subsets of additional cellular phenotypes that might be drug targets and/or biomarkers.
In this study, we aimed to investigate the role of tumor cells in promoting mesenchymal phenotype in ECs by setting up tumor-endothelial co-culture systems in the absence of serum or cytokine supplementations. We initially confirmed the induction of mesenchymal phenotype in Human Umbilical Vein Endothelial Cells (HUVECs) by breast tumor cells. Then, to overcome the barrier of endothelial sensitivity to starvation and tumor cell-induced cell death [19] , we continued our work with the previously described E4-ECs (that we here refer to as ECs) [10, [20] [21] [22] . ECs were produced through transfection of Primary Endothelial Cells (PECs) with adenoviral E4ORF1 gene as described previously [21] . While this transfection provides a low Akt activation allowing endothelial survival in a serum and cytokine-free condition, it does not modify the endothelial phenotype as has been widely used [10, 20, 22] . Besides, activation of Akt in tumor endothelium has been previously reported [23] and our model might thus be more optimal to mimic the crosstalk between ECs and cancer cells in vivo without any background effect. Using breast cancer cells (BCCs), we showed that BCCs in coculture with ECs stimulated transcriptomics modification of ECs partly represented by acquisition of mesenchymal phenotype. While a similar phenomenon (EndMT) has already been described in the developmental and pathological context, we were able to show that tumor cells were capable of stimulating mesenchymal phenotypes in ECs and the tumor-associated ECs retained their endothelial properties while gaining mesenchymal phenotypes. In addition, this transition was reversible and dependent on continuous contact between ECs and BCCs. Subsequently, we showed that the mesenchymal ECs were capable of constituting a pro-tumoral niche responsible for increasing BCC proliferation, mammary stem cell self-renewal, and pro-metastatic properties. Our results also suggest that tumor-promoted mesenchymal shift in ECs is regulated by Smad signaling through the synergistic stimulation of TGFβ and notch pathways.
Methods

Cell culture & reagents
Breast cancer cell lines MDA-MB231 (MDA-231), MCF-7, and HUVEC were purchased from American Type Culture Collection (ATCC, USA). GFP + ECs (ECs) were developed as described previously [21] . Human recombinant Jagged1 and TGFβ1 were obtained from R&D Systems and PeproTech, respectively. Υ-secretase inhibitors (GSI) and SB-431542 were purchased from Sigma (USA). Breast cancer cells (BCCs) were grown in DMEM/ High glucose (HyClone, USA) supplemented with 10% FBS, L-glutamine, non-essential amino acids (NEAA), and penicillin/streptomycin in a humidified incubator with 5% CO 2 . ECs were grown in M199 growth medium (Gibco, USA) supplemented with 20% FBS, 20 ng/ml β-Endothelial Cell Growth Factor (βECG), 20 units/ml heparin and penicillin/streptomycin. The co-cultures were prepared by mixing one part BCCs with 10 parts GFP + ECs (1:10 ratio) and cells were grown in 1:1 ratio of DMEM/High and M199 media in the absence of serum and growth factors (complete starvation). Co-cultivation of BCCs and ECs was performed over 3-5 days under adherent condition.
Sphere forming assay
Sphere forming assay was used to enrich mammary stem cells (mammospheres) as previously described by Dontu [24] . We slightly modified that protocol and co-cultured mammospheres with GFP + ECs at 1:10 ratio under nonadherent condition to obtain mammo-angiospheres. Mammo-angiospheres were therefore composed of both tumor and GFP + endothelial colonies mingling together. Spheres were grown in a so-called "3D media" as described by Dontu and colleagues by using DMEM-F12 (HyClone, USA) supplemented with 2% B27, 20 ng/mL basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), and 5 μg/mL insulin. In order to prevent the formation of cellular aggregates, a highly viscose 3D media was prepared by addition of 0.2% methylcellulose (Sigma, USA). Stem cell enrichment was evaluated by measuring the perimeter of mammospheres or angiospheres with NIH ImageJ 64 software or by quantifying the number of spheres. A GFP filter was used to distinguish angiospheres.
Cell proliferation assay
MDA-231 or MCF-7 cells were co-cultured with GFP + ECs (1:10 ratio) under starvation and ECs survival was assessed at different intervals by trypsinization and repeated manual counting by hemacytometer. A GFP filter was used to distinguish the GFP + ECs from unstained BCCs. In this study, ECs that have been pre-exposed to BCCs are referred to as ECs Mes 
Flow cytometry & cell sorting
Antibodies to human PE-CD31 (560983), AF647-VEcadherin (561567), and fibronectin (FN1, 610077) were purchased from BD Biosciences (USA). AF633-F-actin (phalloidin, 22284) is a product of Invitrogen (USA), vimentin (5741) and α-SMA (ab5694) are from Cell Signaling Technologies and Abcam, respectively (USA). The secondary antibodies were purchased from Invitrogen. GFP + ECs were either cultured alone or co-cultured with BCCs. To stain ECs in mono or co-cultures, cells were initially trypsinized and washed with PBS. For labeling intracellular proteins, cells were initially fixed then permeabilized on ice in freshly prepared 3.7% paraformaldehyde and 0.1% TritonX-100 for 10 minutes/each prior to incubation with primary antibodies (permeabilization by TritonX-100 was not carried out for cell surface proteins). Briefly, cells were resuspended at 1 × 10 6 cells/100 μL density in a staining buffer containing 5% FBS, 1% BSA, 0.2 mM EDTA in PBS. To enhance the specificity of staining, FcR blocking (Miltenyi Biotec, USA) was added at 5 μL/1 × 10 6 cells prior to incubation with primary antibodies. Primary antibodies were then added according to the instructions provided by the manufacturers and incubation was done for 1 hour at 4°C. After washing, cells were stained with secondary antibodies for 30 minutes at 4°C followed by washing. Fluorescent light (FL) was quantified using Fluorescence Activated Cell Sorting (FACS) on a SORP FACSAria II (BD Biosciences), eGFP fluorescence was acquired using a 488 nm blue laser and 510/ 50 nm emission, Phycoerythrin fluorescence (PE) was acquired using a 498 nm blue laser and 575/26 nm emission. Alexa Fluor® 647 fluorescence was obtained with a 650 nm red laser and 660/20 nm emission, while Alexa Fluor® 633 was obtained with 633 nm red laser and 647 nm emission. The figures display the median of fluorescence intensity (MFI) relative to controls. Doublets were excluded by FSC-W × FSC-H and SSC-W × SSC-H analysis, and single stained channels were used to compensate. Fluorescent minus one was used for gating. 10,000-30,000 events were acquired per sample. Finally, data were processed with FACSDiva 6.3 software (BD Biosciences) or Summit 4.3 (Dako).
For sorting GFP + ECs, GFP fluorescence was acquired using 488 nm blue laser and 510/50 nm emission and sorting was done using purity masks [13] . For sorting BCCs, cancer cells were stained with a PE-conjugated dye called PKH26 (Sigma, USA) prior to co-culture and PE fluorescent was acquired using 496/566 nm blue laser and 576 nm emission to separate them from GFP + BCCs were co-cultured under starvation for 3-5 days, and then the cells were sorted as described in the previous section. Sorted ECs or cancer cells were immediately plated and grown at 100% confluence in complete medium to recover overnight. Next, they were continued to culture under complete starvation for 6 hours to impede cellular growth before a wound healing assay was initiated [25] . Finally, the migration capability of cells to close the wound (scratch) was evaluated after 48 hours using NIH ImageJ 64 software.
Tube forming assay
Growth factor reduced Matrigel (BD Biosciences, USA) was thawed at 4°C overnight, and added to each well of a 48-well plate (120 μL/well) and allowed to solidify for 30 minutes at 37°C. GFP + ECs were sorted from BCCs and immediately plated on matrigel at subconfluent density (2.5 × 10 4 cells/well). The formation of capillarylike structures was examined with an inverted microscope after 24 hours and the number of capillary junctions was quantified by analyzing the digitized images.
Immunocytochemistry
Antibodies against PE-CD31 (560983), AF647-VE-Cadherin (561567), and FN1 (610077), CD44 (555478) and desmin (550626) were purchased from BD Biosciences. F-actin (AF633-phalloidin, 22284) is a product of Invitrogen, whereas vimentin (5741) and α-SMA (ab5694) antibodies are products of Cell Signaling Technologies and Abcam, respectively. Anti-fade gold DAPI and secondary antibodies were purchased from Invitrogen. Cells were grown, stained, and imaged on glass chamber slides (Lab-Tek®). Briefly, the adherent cells were washed once with PBS and fixed in 3.7% formaldehyde, then permeabilized in 0.1% Triton X-100 for 20 minutes (no permeabilization required for cell surface proteins). After one wash, the cells were blocked for 30 minutes in a buffer containing 3% FBS and 1% BSA for one hour. Primary antibodies were prepared according to the instruction provided by the manufacturers and incubation was done for two to three hours on a shaker at normal temperature. After washing, the cells were incubated with secondary antibodies for 30 minutes. The fluorescent signals were acquired on a Zeiss Confocal Laser Scanning Microscope 710 (Carl Zeiss).
Immunohistochemistry
All antibodies are listed in the previous section. Formalin-fixed paraffin-embedded (FFPE) sections of neoplastic human breast biopsies were deparaffinized by dipping the slides in xylene for 15 minutes. The sections were rehydrated by immersing them in serial dilution of ethanol for 5 minutes followed by rinsing. Antigen retrieval was performed by boiling the slides in citrate buffer (pH 6.0) for 15 minutes. Snap frozen sections of human xenograft tumors were thawed briefly, fixed and permeabilized as described above. Primary antibody incubation was carried out overnight at 4°C in a moisture chamber after a 30-minute blocking period. Secondary antibodies were incubated for one hour followed by several washes. Slides were then mounted with DAPI.
shRNA transfection
Human shJagged1, scrambled lentiviral particles, and polybrene were purchased from Santa Cruz Biotechnology (USA). In summary, cells were cultured up to 50% confluence and were then treated with polybrene and lentiviral particles containing shRNA against Jagged1 or scrambled particles. Transfected cells were then selected using puromycin, and the down-regulation of Jagged1 was assessed by qPCR.
RNA extraction & qPCR analysis
Total RNA was extracted with RNeasy Mini Kit (250) from Qiagen according to the manufacturer's instructions. The RNA concentration was measured with Nanodrop 8000 spectrophotometer (Thermo Scientific) and 1 μg of RNA was used to produce cDNA with the ProtoScript M-MuLV Taq RT-PCR kit using the oligo dT primers (New England BioLabs). Semi-quantitative realtime analysis (qPCR) was done with a 7500 qPCR System (Applied Biosystems, USA) using a GoTaq 2-step RT-qPCR System (Promega) to amplify the gene of interest following the instructions provided. Primer sequences are listed in Additional file 1: Table S1 .
Protein extraction & western blot analysis
Cells were lysed in RIPA buffer (Sigma) containing protease and phosphatase inhibitors. For each sample, 40 μg of total protein were analyzed by Western blot. Proteins were separated on 10% SDS polyacrylamide gels and electroblotted at 4°C onto polyvinylidene difluoride (PVDF) membranes for one hour. The membranes were blocked in 5% nonfat dry milk or bovine serum albumin (BSA) in 0.1% Tween 20 in Tris-buffered saline prior to incubation with primary antibodies at 4°C overnight. The antibodies included phospho-Smad5 (1:500, Abcam, ab76296), phospho-Smad3 (1:500, Bioss, bs-3425R), Smad5 (1:1000, Cell Signaling, 9517), Smad3 (1:1000, Cell Signaling, 9523), Hes1 (1:200, Millipore), and β-actin (1:3000, Sigma, A2228). Blots were developed using HRP and chemiluminescence peroxidase substrate (ImmunoCruz) (Santa Cruz Biotechnology) and FluroChem HD2 (Cell Biosciences).
RNA extraction & microarray analysis
RNA was isolated as explained above. Two quality control measures were carried out: (1) a spectrophotometric analysis and (2) a size fractionation procedure using a microfluidics instrument (Agilent Technologies). Total RNA (200 ng) was analyzed on Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. Data were analyzed using Partek Software (V6.09.1110-6; Affimetrix), Venny online software (BioinfoGP; CNB-CSIC) and Ingenuity Pathway analysis (Ingenuity Systems, Redwood City, CA). Class comparisons between ECs Norm and ECs
Mes
(three biological replicates of each) were performed to identify gene expression changes with significant expression differences (p < 0.05) and two-fold increase or decrease in expression.
Human xenograft tumor formation in NOD/SCID mice
All animal procedures were approved by the Ethics Committee for animal experimentation of Weill Cornell University (New York, USA). Six-week old female NOD/ SCID mice were purchased from Jackson Laboratories. MDA-231 cells were injected (2 × 10 5 ) with or without 2 × 10 6 ECs (1:10 ratio) in the mice mammary fat pad of NOD/SCID mice. Four mice were assayed for each group. Each mouse received an injection of tumor cells on the left and co-injection of tumor and endothelial cells on the right side. The mice were euthanized and checked for tumor formation 18 and 30 days after inoculation. The extracted tumors were snap frozen for histological analysis.
Ingenuity pathway analysis
We used Ingenuity Pathway Analysis software (IPA) (Ingenuity Systems, Redwood City, CA) for network analysis of EC genes that were differentially regulated upon 
Statistical analysis
All quantitative data are expressed as mean ± standard error of the mean (SEM). Statistical analysis and graphical presentation were performed using SigmaPlot 12 (Systat Software Inc., Chicago, IL) or Excel (Microsoft Corporation). A Shapiro-Wilk normality test, with a p = 0.05 rejection value, was used to test normal distribution of data prior to further analysis. All pairwise multiple comparisons were performed using one-way ANOVA followed by Holm-Sidak posthoc tests for data with normal distribution or, in case of a failed normality test, by Kruskal-Wallis analysis of variance on ranks followed by Tukey posthoc tests. Paired comparisons were performed using Student's t-tests or Mann-Whitney rank sum tests in case of unequal variance or failed normality test. Statistical significance was accepted for p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). All experiments were performed in triplicate and repeated three times (n = 3).
Results
Tumor-associated ECs enhance human xenograft tumor formation and demonstrate a mesenchymal phenotype in breast tumors
To investigate the role of ECs in creating a pro-tumoral niche in vivo, we injected breast tumor cells MDA-231 to the mammary fat pad of NOD/SCID mice with or without ECs. The mice that were co-injected with MDA-231 and ECs showed significantly higher tumor burden with tumors weighing three-fold higher than mice that were only inoculated with MDA-231 cells ( Figure 1A and B). Immunofluorescent imaging demonstrated that co-injected ECs generated functional and viable vessels in xenograft tumors ( Figure 1C ).
To confirm a mesenchymal phenotype in xenograft tumors, tumor sections were examined for the expression of mesenchymal markers such as vimentin and α-SMA. We showed co-expression of mesenchymal and endothelial markers in endothelium of the xenograft tumors ( Figure 1D ). In order to show that the tumor-stimulated mesenchymal properties in ECs might potentially occur in vivo, we stained FFPE sections obtained from breast tumor biopsies with mesenchymal markers. Similar to xenograft tumors, breast tumor endothelium showed a mesenchymal phenotype while maintaining an endothelial trait ( Figure 1E ).
Breast cancer cells promote mesenchymal phenotypes in ECs
To show that cancer cells promote a mesenchymal phenotype in ECs, we initially used Human Umbilical Vein Endothelial Cells (HUVECs). Our flow cytometry results confirmed that MDA-231 cells stimulated a mesenchymal phenotype in HUVECs as shown by upregulation of mesenchymal markers (α-SMA & FSP-1) while maintaining the endothelial trait (shown by CD31 & VE-Cadherin expression) (Additional file 1: Figure  S1 ). Due to oversensitivity of HUVECs to starvation and rapid cell death, we used E4-ECs (ECs) that show relatively low Akt activation and are therefore resistant to serum-free conditions as well as tumor-cell induced apoptosis [19, 21] . We further confirmed that cancer cells could stimulate a mesenchymal trait in ECs. The preservation of vascular phenotype in the co-culture setting was shown by stable expression of VE-cadherin and CD31 in ECs (Figure 2A ). However, we were able to detect a shift toward mesenchymal phenotype represented by increased expressions of fibronectin (FN1), vimentin ( Figure 2B , left panels), and α-SMA as well as stress fibers (F-actin) using confocal imaging ( Figure 2B , right panels). These results were further validated by flow cytometry analyses (Figure 2A-B) . Similar findings were obtained with ECs co-cultured with MCF-7 BCCs (Additional file 1: Figure S2A ). Therefore, the ECs exposed to BCCs that show expression of mesenchymal markers are here referred to as "ECs Figure S2B ). We also checked if tumor-stimulated mesenchymal transition in ECs was contact-dependent by growing ECs in MDA-231 cells conditioned media (CM). We did not detect any changes in the expression of mesenchymal markers in ECs by flow cytometry (Additional file 1: Figure S3A -B).
Additionally, whole transcriptomics analysis was performed on ECs
Mes and ECs Norm . The results showed differential expression of over 1000 genes in ECs Mes as presented in Figure 2D (left panel) (for a list of most significantly modified genes refer to Additional file 2: S4). IPA analysis revealed several functional pathways that were significantly up-regulated, and among these we identified several pathways compatible with a mesenchymal phenotypes such as cell growth and proliferation ( Mes by cocultivating ECs with MDA-231 or MCF-7 followed by sorting and subsequently evaluated their functional properties ( Figure 3A & Additional file 1: Figure S5 ). Since an invasive endothelium was previously implicated in tumor development and metastasis [26] , we compared the migration/invasion property of ECs Mes with ECs Norm by performing a wound healing assay. The results showed that ECs Mes acquired an increased migration/invasion property ( Figure 3B , left) as they closed the wound around three-fold faster than ECs Norm ( Figure 3B , right). It should be noted that the wound healing assay was performed over 48 hours and under complete starvation; therefore, wound closure was mainly the outcome of cell migration and the possibility of cell proliferation was excluded due to lack of serum and cytokines. To measure EC Mes angiogenic potency in comparison to ECs Norm , a conventional tube forming assay was performed ( Figure 3C, left) . The results demonstrated three-fold increase in the capacity of ECs Mes to form tubular branches on matrigel compared to their normal counterparts ( Figure 3C, right) . Since EC proliferation ensures angiogenesis and vasculogenesis [27, 28] Figure 3D ). Without BCCs, ECs
Norm survival rate was about two-fold lower on Day 7 ( Figure 3D, right) .
Finally, as has been recently shown by our group, EC activation triggers an angiocrine switch to allow secretion of angiocrine factors and cytokines that are primordial for tumor growth and tissue regeneration [7] . In our study, the sphere forming assay for constitution of angiospheres was used as a surrogate approach for enriching ECs with activated angiocrine phenotype. Concordantly, a colony forming assay was previously reported as one of several methods used to culture endothelial progenitor cells with neovascularization properties [29] . Hence, we benefitted from the sphere forming assay and cultured ECs Mes under anchorage-independent condition for 3-5 days and compared their angiosphere (colony) forming capacity with ECs Norm . Consistent with our previous data, we showed that ECs Mes displayed greater ability to form angiospheres as compared with ECs Norm ( Figure 3E ). Collectively, our results confirmed a significant increase in cell plasticity toward acquisition of mesenchymal properties in ECs
Mes as shown by their enhanced migratory, angiogenic, angiocrine and survival properties under serum-and cytokine-free conditions.
To investigate the durability of the mesenchymal trait in ECs Mes and to examine the importance of tumor context for its maintenance, we continued to grow and passage ECs
Mes for 10-15 days under normal conditions after sorting them from BCCs (Additional file 1: Figure  S6A ). ECs Norm were cultured in parallel throughout the experiment to serve as controls. Interestingly, the mesenchymal phenotype was reversed in ECs Mes 15 days after sorting from BCCs as indicated by down-regulation of mesenchymal markers by confocal imaging (Additional file 1: Figure S6B ). Therefore, we refer to ECs with reversed mesenchymal phenotype as ECs Reversed . This observation was further confirmed at mRNA level by qPCR (Additional file 1: Figure S6C ). To compare the functional properties of ECs Reversed with the ECs Mes , we performed a wound healing assay that showed 1.5 to 2.4-fold decrease in ECs Reversed ability to close the wound (Additional file 1: Figure S6D ). Consistent with this observation, the result of our tube formation assay also demonstrated a 2.5-fold decrease in the number of tube junctions made by ECs
Reversed as compared to ECs Mes (Additional file 1: Figure S6E ).
ECs
Mes provide a pro-tumoral niche for tumor growth and development To determine a role for ECs Mes in breast cancer progression, we re-exposed ECs Mes to freshly prepared BCCs and evaluated proliferation, sphere forming capacity and invasiveness of tumor cells grown with ECs Mes or ECs Norm . The experimental procedure is illustrated in Figure 4A . Figure S3C ).
Then, we examined how ECs Mes influence the enrichment of mammary stem cells (mammospheres). We cocultivated GFP Figure 4D ). Our results indicate that cancer-endothelial crosstalk potentially modulates EC plasticity; contact with tumor cells triggers a mesenchymal (activated) phenotype in ECs that is reversed once the tumoral context is removed. Thus, cell-to-cell contact seems to be crucial for the initiation and maintenance of the mesenchymal state of ECs Mes and may be regarded as a novel approach for treating cancer. However, a better understanding of the molecular mechanism regulating this interaction seems necessary.
Tumor-stimulated mesenchymal phenotypes in ECs Mes is regulated by synergistic Notch and TGFβ pathways
Previous works demonstrated that TGFβ or notch pathways regulate the EndMT phenomenon during normal and pathological developmental processes [17, 18, [30] [31] [32] [33] .
To investigate the involvement of notch or TGFβ Figure 5A ). Concordantly, our transcriptomics results confirmed the upregulation of several genes involved in EMT or EndMT processes in ECs Mes , among which a notch receptor as well as signaling effectors like Hey-1 and Hes-4 were listed (Table 2) .
Earlier studies pointed out the involvement of distinct cellular receptors, TGFβ/ALK1 (BMPs) triggering Smad1/ 5/8 phosphorylation and TGFβ/ALK5 (activin) stimulating Smad2/3 phosphorylation in endothelial transformation [34] . Our western analysis ruled out the activation of smad3 signaling in ECs Mes ( Figure 5B ). However, our results determined the activation of Smad5 in ECs Mes ( Figure 5C , top lane). Also, transcriptomics data confirmed the up-regulation of BMPR1A receptor in ECs Mes , which was previously shown to mediate BMP-2 and BMP-4 effect in Smad signaling activation (Table 2) [34, 35] .
To confirm a role for endothelial notch and TGFβ in phosphorylation of Smad5 in ECs Mes , ECs Norm were treated with soluble forms of human recombinant Jag1 (4 μg/mL) and TGFβ1 ligands (5 ng/mL). Our western analysis showed Smad5 phosphorylation only in response to treating ECs Norm with Jag1 and TGFβ ligands as was compared with total Smad5 protein ( Figure 5C , top lane). To further verify the synergistic role of Jag1/ notch and TGFβ/Smad5 in this process, we treated ECs Norm with both Jag1 and TGFβ ligands and observed increased level of Smad5 phosphorylation ( Figure 5C , top lane) confirming the synergistic role for the ligands in activation of Smad5. To further validate a role for notch pathway in this process, we showed up-regulation of notch pathway downstream effector Hes-1 in response to treating ECs Norm with Jag1 and/or TGFβ ligands ( Figure 5C , third lane). Band densitometry analyses showed the highest level of Smad5 and Hes-1 activation once ECs
Norm were treated with both ligands simultaneously (Additional file 1: Figure S8-A) .
Additionally, we treated co-cultures of ECs Norm and MDA-231 cells with inhibitors of notch (GSI, 5 μM) and TGFβ (SB-431542, 10 μM) pathways. After sorting ECs, phosphorylation of Smad5 was compared with ECs Mes by western blotting. The results demonstrated that notch and TGFβ inhibition reduced Smad5 phosphorylation ( Figure 5D, left panel) . Additionally, we showed that inhibition of notch and TGFβ pathways down-regulated Hes-1 protein ( Figure 5D, right panel) . Band densitometry analysis confirmed the highest p-Smad5 and Hes-1 inhibition once ECs
Mes were concurrently treated with the inhibitors (Additional file 1: Figure S8B ). Besides, our results indicated that mesenchymal phenotype in ECs Mes were down-regulated when they were treated with GSI and SB (Additional file 1: Figure S8C ). Collectively, our findings suggest a synergistic role for endothelial Jag1 and TGFβ in regulating tumor-stimulated mesenchymal phenotypes in ECs Mes . To further validate our results, we established a stable population of MDA-231 Jag1-KD by using shRNA against Jagged1 on tumor cells and determined Jagged1 downregulation compared to MDA-231
Scrambled by qPCR (Additional file 1: Figure S8D ). Then, down-regulation of notch downstream effectors such as Hey-1 and Hes-1 was compared between ECs that were exposed and sorted from MDA-231
Scrambled or MDA-231
Jag1-KD (Additional file 1: Figure S8E ). Next, the endothelial and mesenchymal phenotype of ECs co-cultured with MDA-231 Jag1-KD was compared to ECs Mes that were grown with MDA-231 Scrambled . The confocal results confirmed stable expression of endothelial and mesenchymal markers such as VE-Cadherin, CD31 in ECs grown with MDA-231 Jag1-KD ( Figure 5E , top). However, mesenchymal markers such as FN1 and F-actin were not up-regulated in those cells (Figure 5E, bottom) . These results were further validated by qPCR analysis ( Figure 5F ). Moreover, in order (See figure on previous page.) Figure 3 ), a wound-healing assay was performed. We observed a reduction in ECs ability to close the gap when grown and sorted from MDA-231 Jag1-KD ( Figure 5G ). Overall, these findings confirm the involvement of notch pathway in regulation of tumorpromoted mesenchymal transitions in ECs Mes .
Discussion
Our main finding is that the tumor cells promote the acquisition of a transient contact-dependent mesenchymal phenotype in ECs contributing to the generation of a pro-tumoral niche. Transforming growth factorβ (TGFβ) and notch pathways seem to be determinant inducers of tumor-fostered mesenchymal phenotype in ECs.
The tumor microenvironment is implicated in the propagation and metastasis of several tumor types [36] [37] [38] . The role of endothelial cells (ECs) -as one the components of tumor stroma-in cancer development were merely thought to involve angiogenesis [26] . Recently, our team demonstrated a novel role for tumor endothelium in tissue repair, self-renewal of HSCs as well as tumor growth and stemness by angiocrine factors [7, 8, 11, 13] . In addition, ECs were previously described as cells that demonstrated a high degree of plasticity under different conditions, a feature that is implicated in tumor development [1, 6] . Tumor-associated endothelial plasticity may be explained in the context of spatiotemporal plasticity (i.e., to change phenotype and function) and reciprocity (i.e., by processing signals received from the environment) that have been earlier explained by Bissell's group to be fundamental in step-wise changes in both tumor cells and their microenvironment [39] [40] [41] . Accordingly, plasticity and reciprocity account for the morphologic and functional heterogeneity driven by mechanisms such as cell-to-cell signaling to allow cells to cope with altering environmental conditions [42] [43] [44] . These mechanisms might be modulated by tumor and stromal cells crosstalk to co-evolve in a dynamic microenvironment [44, 45] . Hence, our work emphasizes a crosstalk mechanism that is absolutely dependent on cell-to-cell contact between tumor and endothelium. The focal points of interaction between tumor and vasculature might not be abundantly present within the tumor bulk, but may potentially serve as miniature sites within the tumor microenvironment that may enhance neovascularization leading to increased tumor growth and metastasis.
In this study, we demonstrated that tumor cells are capable of promoting mesenchymal phenotype in their neighboring endothelium. In return, the ECs Mes significantly contributed to tumor development. Although we initially observed this phenomenon in HUVECs, we continued our work with the widely used E4-ECs [21] to circumvent the hurdle of tumor-induced HUVEC apoptosis in co-cultures that was also reported previously by Kebers et al. [19] . The mesenchymal transformation in tumor endothelium in conjunction with loss of endothelial phenotype has been previously described in EndMT phenomenon as a mechanism for generation of CAFs [17, 18] . However, the acquisition of mesenchymal phenotype with maintenance of endothelial trait and its significance for tumor propagation has never been explained earlier. The importance of this phenomenon may be explained by enhanced survival, mobility and angiocrine properties as well as the angiogenic ability of ECs Mes . Our transcriptomics data further validate our hypothesis by showing up-regulation of pathways involved in cell development, signaling, and movement in addition to vascular system expansion and blood vessel formation.
The present work also focused on looking into the role of mesenchymal endothelium (ECs Mes ) in breast tumor progression. In vivo, human xenograft tumor formation was enhanced by co-injection of ECs and tumor cells in NOD/SCID mice showing the up-regulation of mesenchymal markers in tumor-associated ECs. Also, by developing adherent (2D) and non-adherent (3D) co-(See figure on previous page.) Figure 4 ECs Mes provide a pro-tumoral niche for tumor growth and development. A) Schematic representation of the experimental procedures carried out for evaluating the role of ECs Mes in tumor development. ECs Mes were acquired following the steps described in Figure 3A .
Next, ECs
Mes and ECs Norm were co-cultured with BCCs to compare their effects on cancer cell survival, cancer stem cell enrichment and cancer cell invasiveness. B) Cell proliferation assay and phase contrast imaging showing survival or proliferation of MDA-231 cancer cells when cultured alone or co-cultured with ECs Mes or ECs culture systems, the role of ECs Mes in cancer proliferation, stemness and invasiveness was evaluated. Based on a study by Maffini et al., the preliminary target for a carcinogen is tumor stroma and mutations in mammary epithelial cells are not sufficient for tumor initiation [46] . Campbell's group earlier demonstrated that a modified stroma preferentially promotes the outgrowth of abnormal epithelial cells [44, 47] . Also, a study conducted by Moses and colleagues demonstrated that cell signaling abnormalities in stromal fibroblasts promoted mammary tumorigenesis in a non-cell-autonomous manner [48, 49] . Therefore, it is primordial to study tumor microenvironmental changes that occur during cancer progression. In addition to influencing tumor initiation and progression, these changes significantly impact the efficacy of cancer therapy specifically when targeting stroma-regulated pathways [50] . In accordance with these reports, our work highlighted the importance of tumor contexture in fostering phenotypic changes in ECs Mes and how this alteration impact tumor proliferation, survival, stemness and pro-metastatic properties. Therefore, elucidation of the mechanisms underlying microenvironment alteration will be beneficial in targeting stroma to combat cancer.
TGFβ was previously suggested as an important role player in the EndMT process during normal and pathological situations [30, 51, 52] . In addition, notch signaling was shown to promote EndMT during both cardiac development and oncogenic transformation [32, 33] . In this study, we showed a similar phenomenon through which tumor cells enhanced mesenchymal phenotypes in ECs while preserving the endothelial phenotypes. We showed that the tumor-stimulated processes leading to creation of EC Mes are also mediated by phosphorylation of TGFβ/Smad1/5 in synergy with notch pathway activation. Notch involvement in the regulation of TGFβ signaling in ECs was previously reported [32, 34, 53, 54] . Both synergy and antagonism between notch and TGFβ signaling were described in ECs in a contextdependent manner [34, [53] [54] [55] [56] [57] [58] [59] . Our data confirmed that tumor-activated TGFβ/Smad1/5 phosphorylation was regulated by synergistic activation of notch and TGFβ pathway by showing that TGFβ and Jag1 were capable of inducing Smad5 phosphorylation as well as Hes1 up-regulation. Simultaneous inhibition of notch and TGFβ pathways not only impaired Smad5 phosphorylation but also impaired the acquisition of mesenchymal traits by ECs.
Earlier reports by Karsan's group emphasized the importance of Smad1/5 phosphorylation in promoting proliferation and migration of ECs [34] . Also, phosphorylation of Smad1/5/8 was implicated in ECs migration [60] . Consistent with these observations, we demonstrated that tumor interaction with ECs stimulated TGFβ/Smad1/5 phosphorylation possibly resulting in gain of functional advantages by ECs Mes . Since the acquired mesenchymal phenotypes in ECs Mes seem to be a reversible phenomenon, targeted inhibition of the molecular modulators of this process may therefore be considered as potential therapeutic approaches.
Our findings of the tumor-promoted mesenchymal phenotype in ECs Mes might partly explain the molecular mechanisms that govern ECs plasticity. Interestingly, our transcriptomics data while confirming mesenchymal traits, demonstrated modifications of over 1000 genes that might be relevant to tumor endothelial biology and play roles in phenomena such as resistance to treatment and metastasis. As such, up-regulation of previously described angiocrine factors such as IL6, Jag1, and CXCR4 [61] 
in ECs
Mes may have potentially participated in the constitution of a pro-tumoral niche; however, the exact determinants of the angiocrine niche need to be clarified in future studies. While in our settings a change to ECs Mes found to be transient, its permanence has not yet been carefully addressed in any study. However, the constitution of a transient niche might offer a window for the constitution of residual or resistant disease. Additional investigations involving in vivo approach are required to validate our data in order to design new drugs for impairing tumor-EC interaction as a mean to treat cancer.
Conclusion
Although the importance of microenvironment modification in tumor development is already known, the molecular changes underlying these alterations is not well recognized. ECs are essential components of microenvironment, which influence tumor progression by establishing the tumor vascular niche and producing angiocrine factors. In addition, ECs seem to adapt to the context they reside in by showing plasticity. This study demonstrated that in tumor microenvironment, ECs are instructed through tumor-derived inducers to proceed to an activation state characterized by up-regulation of mesenchymal phenotypes. Since this interaction strongly relies on cellto-cell contact between tumor cell and endothelium, it may not be widely detectable in tumor microenvironment. Where the cell interaction occurs, the new mesenchymal trait along with the intrinsic endothelial properties may allow ECs
Mes to create a pro-tumoral niche supporting tumor progression and metastasis. Since EC Mes mesenchymal characteristic is transient and strongly dependent on tumor contexture, it may introduce a new therapeutic target for treating cancer. 
